Barclays’s VITAE PHARMACEUTICALS INC COMMON STOCK VTAE Stock Holding History

Barclays’s Portfolio VTAE Stock Details VTAE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q4	–	Sell	-43,855	Closed	-$917K	–	7095
2016 Q3	$917K	Buy	43,855 +36,785	+520%	+$424K	﹤0.01%	2708
2016 Q2	$77K	Buy	7,070 +6,935	+5,137%	+$59.3K	﹤0.01%	4581
2016 Q1	$1K	Sell	135 -399	-75%	-$3.63K	﹤0.01%	6079
2015 Q4	$10K	Buy	534 +464	+663%	+$6.38K	﹤0.01%	5422
2015 Q3	$1K	Sell	70 -182	-72%	-$1.93K	﹤0.01%	6746
2015 Q2	$4K	Buy	252 +53	+27%	+$720	﹤0.01%	6632
2015 Q1	$2K	Sell	199 -257	-56%	-$3.47K	﹤0.01%	6929
2014 Q4	$7K	Buy	+456	New	+$6.67K	﹤0.01%	6906

Barclays's VTAE Position: Q4 2016 in Review

Barclays sold out of VITAE PHARMACEUTICALS INC COMMON STOCK (VTAE) in Q4 2016, closing a stake of 43,855 shares — an estimated $917K sold.

Barclays first reported a position in VTAE in Q4 2014 and held it in 8 quarters. The position peaked at $917K in Q3 2016. 0 funds tracked by Wall St. Rank hold VTAE as of Q4 2016.

Barclays reported no remaining VITAE PHARMACEUTICALS INC COMMON STOCK position as of Q4 2016 after selling out during the quarter.
Barclays sold 43,855 VITAE PHARMACEUTICALS INC COMMON STOCK shares in Q4 2016, an estimated $917K.
Barclays first reported a position in VITAE PHARMACEUTICALS INC COMMON STOCK in Q4 2014 and held it in 8 quarters.
Barclays's VITAE PHARMACEUTICALS INC COMMON STOCK position peaked at $917K in Q3 2016.
0 funds tracked by Wall St. Rank held VITAE PHARMACEUTICALS INC COMMON STOCK as of Q4 2016.

Based on Barclays's 13F filing for Q4 2016, filed 14 Feb 2017.